Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ping An Pays $245 Million for Stake in Japan's Tsumura, a TCM Company

publication date: Sep 27, 2017

China's Ping An Insurance paid $245 million to acquire a 10% stake in Japan's Tsumura, an herbal drugmaker. Tsumura controls 84% of Japan's market for prescription Kampo medicine, the Japanese development of traditional Chinese medicine that started in the seventh century. The two companies will set up a JV to bring Kampo medicines to China, "offering more choice" to China's people, they added. More details....

Stock Symbols: (HK: 2318; SHA: 601318) (TYO: 4540)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.